Anti-IL-17A Monoclonal Antibody(Ixekizumab),Starter_specification/price/image

Product Detail
Company Profile

Product Specification

Host	Human
Antigen	IL-17A
Synonyms	Interleukin-17A, Cytotoxic T-lymphocyte-associated antigen 8 (CTLA-8), CTLA8, IL17
Accession	Q16552
Clone Number	S-SC008
Antibody Type	Recombinant mAb
Isotype	IgG4,k
Application	Blocking of IL-17A signaling Functional assays
Purification	Protein A
Concentration	2 mg/ml
Endotoxin	<1EU/mg
Conjugation	Unconjugated
Physical Appearance	Liquid
Storage Buffer	PBS pH7.4, containing no preservative
Stability & Storage	12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution

application	dilution	species
ELISA	1.221-5000 ng/ml

Background

Ixekizumab is an injectable medication for the treatment of autoimmune diseases. It is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.